CellaVision has been approved for listing on NASDAQ OMX Stockholm
(Thomson Reuters ONE) -
The Stockholm Stock Exchange listing committee has approved CellaVision AB
(publ) for listing on NASDAQ OMX Stockholm, Small Cap. First day of trading will
be 31 May 2010.
The listing means that the trading in CellaVision shares is moved from the
marketplace NASDAQ OMX First North Premier ("First North") to NASDAQ OMX
Stockholm. First day of trading is 31 May 2010. The listing of CellaVision's
share on First North thereby ceases and last day of trading on First North is on
28 May 2010. The Company's shareholders do not have to take any action in
connection with the listing on NASDAQ OMX Stockholm. No issue of new shares is
taking place in connection with the listing on NASDAQ OMX Stockholm. The share
will be traded under the same ticker as before; CEVI, ISIN-code SE0000683484.
"Since our first year of revenue in 2001, CellaVision has demonstrated strong
growth and rising profitability. The listing on NASDAQ OMX Stockholm is part of
CellaVision's growth strategy and is made to facilitate for institutional
investors to invest in the CellaVision share and creating prerequisites for
improved liquidity in the share, which increases the flexibility in the
Company's continued expansion. Furthermore, the listing is expected to bring
increased attention from customers and partners, the stock market, media and
other external stakeholders, thus increasing CellaVision's exposure." says
Yvonne Mårtensson, CEO of CellaVision.
A prospectus (in Swedish only) is available at the company
website;www.cellavision.com/prospekt
the prospectus the following financial goals (not previously publicised) for
CellaVision are included:
CellaVision's financial target is to grow its revenue with at least 15% per
year, on average over a business cycle, with an operating margin exceeding 15%.
ABG Sundal Collier acted as financial advisor in connection with the listing
process.
For more information, please contact:
Lars Gatenbeck, Chairman of the Board, CellaVision AB
Tel: +46 70 535 44 44, E-mail:lars.gatenbeck(at)lifeequity.se
Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46 708 33 77 82, E-mail:yvonne.martensson(at)cellavision.se
Johan Wennerholm, CFO, CellaVision AB
Tel: +46 708 33 81 68, E-mail:johan.wennerholm(at)cellavision.se
About CellaVision
CellaVision AB (publ) develops, markets, and sells market leading image analysis
based systems for routine analysis of blood and other body fluids. The company
has a core competence in development of software and hardware for automatic
image analysis of cells and cell changes for applications in health and medical
care. The company develops and markets systems for automatic differentials of
white blood cells and red morphology, and software for education and quality
assurance of differentials. The company's associates have expertise in advanced
imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has subsidiaries
in the US, Canada and Japan. For more information, please
visitwww.cellavision.com
[HUG#1418206]
Unternehmensinformation / Kurzprofil:
Datum: 25.05.2010 - 17:59 Uhr
Sprache: Deutsch
News-ID 21434
Anzahl Zeichen: 0
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 211 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision has been approved for listing on NASDAQ OMX Stockholm"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
